Philip C. Mack
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Philip C. Mack has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- David R. Gandara
University of California Davis Comprehensive Cancer Center, Sacramento, CA
12 shared publications David R. Gandara
Division of Hematology-Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Davis, CA
7 shared publicationsPrimo N. Lara
Division of Hematology-Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Davis, CA
6 shared publicationsWilliam S. Holland
Division of Hematology-Oncology, Department of Internal Medicine, University of California Davis Comprehensive Cancer Center, Davis, CA
6 shared publicationsPrimo Lara
University of California Davis Comprehensive Cancer Center, Sacramento, CA
5 shared publications- Paul H. Gumerlock
Cancer and Molecular Research Laboratory, University of California Davis Cancer Center, 4501 X Street, Sacramento, CA 95817, USA
4 shared publications
Latest Publications
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 4566
Everolimus (EVE) exposure as a predictor of toxicity (Tox) in renal cell cancer (RCC) patients (Pts) in the adjuvant setting: Results of a pharmacokinetic analysis for SWOG S0931 (EVEREST), a phase III study (NCT01120249).
4566 Background: S0931 is assessing recurrence-free survival in RCC pts randomized to receive EVE versus placebo for one year following nephrectomy. To date, there has been a higher than expected dropout rate due to bothersome tox. Previous reports have shown an association between EVE trough levels and both tox and disease response in RCC pts. Therefore, we have assessed EVE trough levels to evaluate the relationship between measured exposure and probability of tox. This analysis has been approved by the DSMC. Methods: Patients received 10 mg daily EVE or placebo for nine 6-week cycles. Pre-dose whole blood samples collected pre-cycle 2 and pre-cycle 3 were analyzed for EVE. Pts with pre-cycle 2 and/or pre-cycle 3 EVE results were used in the analysis. When both trough levels were available, results were averaged. Pts were segregated into quartiles (Q) based on EVE levels and logistic regression was used to model the following adverse event outcomes using EVE trough as a predictor; any grade 3+ tox, grade 2+ triglycerides, grade 2+ hyperglycemia, grade 2+ oral mucositis, grade 2+ rash, and premature stopping of EVE. Hazard and odds ratios were adjusted for age, BMI and performance status. Results: This study reached its accrual goal and closed on 9/15/2016 with 1545 (775 EVE) randomized patients. A total of 386 pts are included in this preliminary analysis. Median EVE trough was 12.8 ng/mL (range 3.1, 75.6) per 10 mg dose. Event rates for tox were: any grade 3+ tox = 46%, grade 2+ triglycerides = 33%, grade 2+ hyperglycemia = 15%, grade 2+ oral mucositis = 34%, grade 2+ rash = 15%, and premature stopping of EVE = 40%. The risk of grade 2+ triglycerides was increased in Q2 and Q3 vs Q1 (OR = 2.95; p = 0.001 and OR = 3.48; p < 0.001). The risk of grade 2+ rash was increased in Q2 and Q4 vs Q1 (OR = 2.95; p = 0.02 and OR = 3.20; p = 0.01). There was also a trend towards an increased risk of any grade 3+ tox in Q3 vs Q1 (OR = 1.72; p = 0.07). Conclusions: This analysis has identified significant associations between EVE exposure and the probability of tox. EVE analysis is ongoing and the final results will be presented. Clinical trial information: NCT01120249.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 4566
Everolimus (EVE) exposure as a predictor of toxicity (Tox) in renal cell cancer (RCC) patients (Pts) in the adjuvant setting: Results of a pharmacokinetic analysis for SWOG S0931 (EVEREST), a phase III study (NCT01120249).
4566 Background: S0931 is assessing recurrence-free survival in RCC pts randomized to receive EVE versus placebo for one year following nephrectomy. To date, there has been a higher than expected dropout rate due to bothersome tox. Previous reports have shown an association between EVE trough levels and both tox and disease response in RCC pts. Therefore, we have assessed EVE trough levels to evaluate the relationship between measured exposure and probability of tox. This analysis has been approved by the DSMC. Methods: Patients received 10 mg daily EVE or placebo for nine 6-week cycles. Pre-dose whole blood samples collected pre-cycle 2 and pre-cycle 3 were analyzed for EVE. Pts with pre-cycle 2 and/or pre-cycle 3 EVE results were used in the analysis. When both trough levels were available, results were averaged. Pts were segregated into quartiles (Q) based on EVE levels and logistic regression was used to model the following adverse event outcomes using EVE trough as a predictor; any grade 3+ tox, grade 2+ triglycerides, grade 2+ hyperglycemia, grade 2+ oral mucositis, grade 2+ rash, and premature stopping of EVE. Hazard and odds ratios were adjusted for age, BMI and performance status. Results: This study reached its accrual goal and closed on 9/15/2016 with 1545 (775 EVE) randomized patients. A total of 386 pts are included in this preliminary analysis. Median EVE trough was 12.8 ng/mL (range 3.1, 75.6) per 10 mg dose. Event rates for tox were: any grade 3+ tox = 46%, grade 2+ triglycerides = 33%, grade 2+ hyperglycemia = 15%, grade 2+ oral mucositis = 34%, grade 2+ rash = 15%, and premature stopping of EVE = 40%. The risk of grade 2+ triglycerides was increased in Q2 and Q3 vs Q1 (OR = 2.95; p = 0.001 and OR = 3.48; p < 0.001). The risk of grade 2+ rash was increased in Q2 and Q4 vs Q1 (OR = 2.95; p = 0.02 and OR = 3.20; p = 0.01). There was also a trend towards an increased risk of any grade 3+ tox in Q3 vs Q1 (OR = 1.72; p = 0.07). Conclusions: This analysis has identified significant associations between EVE exposure and the probability of tox. EVE analysis is ongoing and the final results will be presented. Clinical trial information: NCT01120249.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 9030
Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions.
9030 Background: EGFR exon 20 insertions (Ex20Ins), the 3rd most common EGFR activating mutation, are generally unresponsive to 1st and 2nd generation EGFR-TKIs. Development of EGFR-TKIs that effectively target NSCLC with Ex20Ins mutations represents a major unmet need. Osimertinib is an EGFR TKI approved for the treatment of advanced NSCLC harboring EGFR T790M, but the potential of osimertinib remains to be fully assessed in patients (pts) with Ex20Ins NSCLC. Methods: CRISPR engineered Ex20Ins cell line xenografts representing the two most common Ex20Ins (D770_N771InsSVD and V769_D770InsASV) and pt derived xenograft (PDX) of 3 EGFR Ex20Ins (V769_D770InsASV, M766_A767insASV, H773_V774insNPH) were used for in vivo experiments. Xenografts were treated by oral gavage with vehicle, erlotinib (50 mg/kg/day) or afatinib (20 mg/kg/day), osimertinib metabolite AZ5104 (50 mg/kg/day) and osimertinib (25 mg/kg/day) and assessed for tumor growth inhibition (TGI). Immunoblotting was performed for EGFR and relevant signaling pathways. A pt from whom the V769_D770InsASV Ex20ins PDX was derived was treated on a UC Davis IRB approved protocol with osimertinib at 160 mg PO once-daily (QD). Results: At completion of treatment, QD administration of osimertinib or AZ5104 induced significant TGI in xenografts across the 4 EGFR Ex20ins tested (range 60-95% TGI, p < 0.001 compared to control for all models) that was superior to either afatinib or erlotinib. Robust decrease in p-EGFR, p-ERK, p-Akt, p-Stat3 was observed with osimertinib treatment. The patient corresponding to the V769_D770InsASV Ex20ins PDX treated with osimertinib exhibited clinical improvement and tumor shrinkage; unfortunately he was found to have interstitial pneumonitis that necessitated drug discontinuation. Conclusions: Osimertinib at clinically representative doses has in vivo activity across multiple EGFR Ex20ins that comprising the most common Ex20ins detected in patients (~50% prevalence); metabolite AZ5104 may contribute to efficacy. Tumor shrinkage was observed in a patient with lung cancer harboring an Ex20ins treated for a limited time with osimertinib. Based on this in vivo xenograft and pt data, osimertinib warrants further study in pts with EGFR Ex20ins NSCLC.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , 9030
Antitumor activity of osimertinib in NSCLC harboring EGFR exon 20 insertions.
9030 Background: EGFR exon 20 insertions (Ex20Ins), the 3rd most common EGFR activating mutation, are generally unresponsive to 1st and 2nd generation EGFR-TKIs. Development of EGFR-TKIs that effectively target NSCLC with Ex20Ins mutations represents a major unmet need. Osimertinib is an EGFR TKI approved for the treatment of advanced NSCLC harboring EGFR T790M, but the potential of osimertinib remains to be fully assessed in patients (pts) with Ex20Ins NSCLC. Methods: CRISPR engineered Ex20Ins cell line xenografts representing the two most common Ex20Ins (D770_N771InsSVD and V769_D770InsASV) and pt derived xenograft (PDX) of 3 EGFR Ex20Ins (V769_D770InsASV, M766_A767insASV, H773_V774insNPH) were used for in vivo experiments. Xenografts were treated by oral gavage with vehicle, erlotinib (50 mg/kg/day) or afatinib (20 mg/kg/day), osimertinib metabolite AZ5104 (50 mg/kg/day) and osimertinib (25 mg/kg/day) and assessed for tumor growth inhibition (TGI). Immunoblotting was performed for EGFR and relevant signaling pathways. A pt from whom the V769_D770InsASV Ex20ins PDX was derived was treated on a UC Davis IRB approved protocol with osimertinib at 160 mg PO once-daily (QD). Results: At completion of treatment, QD administration of osimertinib or AZ5104 induced significant TGI in xenografts across the 4 EGFR Ex20ins tested (range 60-95% TGI, p < 0.001 compared to control for all models) that was superior to either afatinib or erlotinib. Robust decrease in p-EGFR, p-ERK, p-Akt, p-Stat3 was observed with osimertinib treatment. The patient corresponding to the V769_D770InsASV Ex20ins PDX treated with osimertinib exhibited clinical improvement and tumor shrinkage; unfortunately he was found to have interstitial pneumonitis that necessitated drug discontinuation. Conclusions: Osimertinib at clinically representative doses has in vivo activity across multiple EGFR Ex20ins that comprising the most common Ex20ins detected in patients (~50% prevalence); metabolite AZ5104 may contribute to efficacy. Tumor shrinkage was observed in a patient with lung cancer harboring an Ex20ins treated for a limited time with osimertinib. Based on this in vivo xenograft and pt data, osimertinib warrants further study in pts with EGFR Ex20ins NSCLC.
- 1 May 2017
- Published by Elsevier in Clinical Lung Cancer
- Vol. 18 (3) , 281-285
Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer
- 1 May 2017
- Published by Elsevier in Clinical Lung Cancer
- Vol. 18 (3) , 281-285
Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non–Small-Cell Lung Cancer
- 1 October 2016
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 11 (10) , S168-S169
O.02: Plasma Next Generation Sequencing of Over 5,000 Advanced Non-Small Cell Lung Cancer Patients With Clinical Correlations
- 1 October 2016
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 11 (10) , S168-S169
O.02: Plasma Next Generation Sequencing of Over 5,000 Advanced Non-Small Cell Lung Cancer Patients With Clinical Correlations
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 9082
Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC).
9082 Background: Bevacizumab (Bev) combined with chemotherapy improves survival in selected patients (pts) with advanced, nonsquamous NSCLC. However, the benefit of Bev has been questioned in certain populations and optimal selection criteria are debated. Methods: SWOG S0819 randomly assigned 1,313 eligible pts with advanced NSCLC to chemotherapy (+/- Bev) with or without cetuximab. Protocol defined criteria for Bev Exclusion (BE) were > 50% squamous cell (SCCA), cavitary lung lesion, hemoptysis ( > 1/2 tsp), coagulopathy, CNS metastasis (until 6/2013), non-healing wound or fistula, anticoagulation, platelet inhibitor, or INR > 1.5. Investigators or pts could also choose BE assignment. We conducted subset analyses to compare the baseline characteristics and treatment outcomes for Bev-included (BI) versus BE pts, as well as BE subsets defined by the protocol (BE-Inappropriate) or patient/investigator choice (BE-Choice). Results: BI pts (42.2%) had superior outcomes to BE pts (Table). The reason for BE was ascertained in 94.2%; most commonly SCCA (44.4%), choice (20%), and anticoagulant or platelet inhibitor (19.1%). Multiple reasons were present in 25.6%. There were no significant differences in age, gender, race/ethnicity, PS, or weight loss between BI and BE pts and no differences between BE-Choice and BE-Inappropriate pts. BE-Choice pts had improved PFS but not OS compared to BE-Inappropriate pts. Conclusions: BI pts with advanced NSCLC on S0819 had better survival than BE pts, approximating those of ECOG 4599. The demographics of BI, BE-Choice, and BE-Inappropriate pts were similar; however, BE-Choice pts had survival outcomes more similar to BE-Inappropriate pts than to those treated with Bev. Support: NIH/NCI/NCTN grants SWOG: CA180888, CA180819; ECOG/ACRIN: CA180820; Alliance: CA180821; and in part by Eli Lilly and Company Clinical trial information: NCT00946712.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 9082
Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC).
9082 Background: Bevacizumab (Bev) combined with chemotherapy improves survival in selected patients (pts) with advanced, nonsquamous NSCLC. However, the benefit of Bev has been questioned in certain populations and optimal selection criteria are debated. Methods: SWOG S0819 randomly assigned 1,313 eligible pts with advanced NSCLC to chemotherapy (+/- Bev) with or without cetuximab. Protocol defined criteria for Bev Exclusion (BE) were > 50% squamous cell (SCCA), cavitary lung lesion, hemoptysis ( > 1/2 tsp), coagulopathy, CNS metastasis (until 6/2013), non-healing wound or fistula, anticoagulation, platelet inhibitor, or INR > 1.5. Investigators or pts could also choose BE assignment. We conducted subset analyses to compare the baseline characteristics and treatment outcomes for Bev-included (BI) versus BE pts, as well as BE subsets defined by the protocol (BE-Inappropriate) or patient/investigator choice (BE-Choice). Results: BI pts (42.2%) had superior outcomes to BE pts (Table). The reason for BE was ascertained in 94.2%; most commonly SCCA (44.4%), choice (20%), and anticoagulant or platelet inhibitor (19.1%). Multiple reasons were present in 25.6%. There were no significant differences in age, gender, race/ethnicity, PS, or weight loss between BI and BE pts and no differences between BE-Choice and BE-Inappropriate pts. BE-Choice pts had improved PFS but not OS compared to BE-Inappropriate pts. Conclusions: BI pts with advanced NSCLC on S0819 had better survival than BE pts, approximating those of ECOG 4599. The demographics of BI, BE-Choice, and BE-Inappropriate pts were similar; however, BE-Choice pts had survival outcomes more similar to BE-Inappropriate pts than to those treated with Bev. Support: NIH/NCI/NCTN grants SWOG: CA180888, CA180819; ECOG/ACRIN: CA180820; Alliance: CA180821; and in part by Eli Lilly and Company Clinical trial information: NCT00946712.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e16121
Randomized phase 2 study of trebananib (AMG 386) with or without continued anti-vascular endothelial growth factor (VEGF) therapy in patients (pts) with renal cell carcinoma (RCC) who have progressed on bevacizumab, pazopanib, sorafenib, or sunitinib.
E16121 Background: In RCC, Angiopoietin (Ang) 2 is elevated at the time of progression on anti-VEGF therapy and may contribute to resistance. We tested trebananib, an Ang 1 and 2 neutralizing peptibody in pts with RCC progressing on anti-VEGF treatment. Methods: Pts with measurable RCC progressing despite an anti-VEGF agent within 12 weeks, any number of prior treatments, good PS and adequate organ function, were randomized to trebananib 15 mg/kg IV weekly without (arm A) or with (arm B) continuation of the prior anti-VEGF agent. After randomization, pts underwent a pre-treatment tumor biopsy. The primary endpoint for each arm was tumor response (RECIST 1.1), evaluated every 12 weeks. Each arm was a Simon Optimum design planned for 39 pts, interim analysis after 17 pts, with alpha = 0.10 and beta = 0.10. Secondary endpoints included progression free survival (PFS) and adverse events (AEs). Results: Of 40 enrolled pts, 35 started treatment (17 arm A, 18 arm B) with median age 61 (39-77) and 3 prior treatments (1-8). Four died prior to documented progression and 24 progressed as their 1st event. At interim analysis, 1 response (in Arm B, trebananib + pazopanib) was observed. Median PFS of 2.7 (95% C.I. 2.3-4.7) months in arm A and 3.4 (95% C.I. 2.7-8.3) months in arm B did not support continued study. Common AEs, mostly grade 1-2, included fatigue, hypertension, and edema, and were numerically higher in arm B. In arm A, 6/17 treated pts (35%) experienced a Grade 3+ AE attributed to trebananib. In Arm B 8/15 pts (53%) with follow up experienced a Grade 3+ AE attributed to combo treatment. The most common grade 3+ AEs were hypertension and dyspnea. A possibly related unwitnessed cardiac arrest occurred on arm B. Conclusions: While tolerable, trebananib either without or with continued anti-VEGF therapy did not show promising activity in RCC pts who recently progressed on anti-VEGF therapy alone. Analysis of pre-treatment research tumor biopsies from this study will provide insights into anti-VEGF therapy resistance, including the role of Ang signaling and the lack of efficacy of these regimens. Clinical trial information: NCT01664182.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e16121
Randomized phase 2 study of trebananib (AMG 386) with or without continued anti-vascular endothelial growth factor (VEGF) therapy in patients (pts) with renal cell carcinoma (RCC) who have progressed on bevacizumab, pazopanib, sorafenib, or sunitinib.
E16121 Background: In RCC, Angiopoietin (Ang) 2 is elevated at the time of progression on anti-VEGF therapy and may contribute to resistance. We tested trebananib, an Ang 1 and 2 neutralizing peptibody in pts with RCC progressing on anti-VEGF treatment. Methods: Pts with measurable RCC progressing despite an anti-VEGF agent within 12 weeks, any number of prior treatments, good PS and adequate organ function, were randomized to trebananib 15 mg/kg IV weekly without (arm A) or with (arm B) continuation of the prior anti-VEGF agent. After randomization, pts underwent a pre-treatment tumor biopsy. The primary endpoint for each arm was tumor response (RECIST 1.1), evaluated every 12 weeks. Each arm was a Simon Optimum design planned for 39 pts, interim analysis after 17 pts, with alpha = 0.10 and beta = 0.10. Secondary endpoints included progression free survival (PFS) and adverse events (AEs). Results: Of 40 enrolled pts, 35 started treatment (17 arm A, 18 arm B) with median age 61 (39-77) and 3 prior treatments (1-8). Four died prior to documented progression and 24 progressed as their 1st event. At interim analysis, 1 response (in Arm B, trebananib + pazopanib) was observed. Median PFS of 2.7 (95% C.I. 2.3-4.7) months in arm A and 3.4 (95% C.I. 2.7-8.3) months in arm B did not support continued study. Common AEs, mostly grade 1-2, included fatigue, hypertension, and edema, and were numerically higher in arm B. In arm A, 6/17 treated pts (35%) experienced a Grade 3+ AE attributed to trebananib. In Arm B 8/15 pts (53%) with follow up experienced a Grade 3+ AE attributed to combo treatment. The most common grade 3+ AEs were hypertension and dyspnea. A possibly related unwitnessed cardiac arrest occurred on arm B. Conclusions: While tolerable, trebananib either without or with continued anti-VEGF therapy did not show promising activity in RCC pts who recently progressed on anti-VEGF therapy alone. Analysis of pre-treatment research tumor biopsies from this study will provide insights into anti-VEGF therapy resistance, including the role of Ang signaling and the lack of efficacy of these regimens. Clinical trial information: NCT01664182.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e20561
Interrogating MEK inhibition in a KRAS-mutant lung cancer patient-derived xenograft (PDX) resource.
E20561 Background: Constitutively activating KRAS mutations (mt) comprise ~28% of lung adenocarcinoma. Despite their accepted role as oncogenic drivers, effective targeted intervention remains elusive. KRAS mts are heterogeneous, with multiple amino acid substitutions differentially associated with patient smoking status and tumor biology, modified further by variable gene amplification levels and co-mt patterns. To identify characteristics of KRAS-mt lung cancers that benefit from MEK inhibition, we investigated the activity of trametinib in a heterogeneous series of KRAS-mt PDX models selected for differences in genomic makeup. Methods: Clinically annotated patient tumor (biopsy, resection or pleural effusion) was implanted subcutaneously into the flank of NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. The resultant PDXs were analyzed for driver mts (JAX 358 CTP panel); copy number variants and global RNA expression (Affymetrix arrays; RNA sequencing). PDX cohorts (n = 6-10) were treated with trametinib at 2-3mg/kg p.o. QDx5/week for 4 weeks, with follow-up until tumors reached pre-determined size. Parallel pharmacodynamic (PD) studies were conducted at 4 & 24h in select models by immunoblotting. Results: To date, 18 KRAS-mt PDX lung cancer models have been established, harboring KRAS G12C, G12D, G12A, G12S or G13R substitutions. 16 models co-harbored TP53mts. Other co-mts of interest included STK11, ATM, Keap1 & BRCA1/2 disrupting mutations, and one model with PI3K E542K. 37% exhibited KRAS gene amplification. Trametinib induced statistically significant tumor growth inhibition in 5 of 9 models tested to date. Characteristics of responsive models included non-G12C KRAS mt with concurrent gene amplification. PD analysis revealed reduction in both MEK and ERK phosphorylation in responsive models. Non-responders showed negligible effect on pERK. Conclusions: In KRAS-mt lung cancer PDX models, single-agent trametinib resulted in partial growth inhibition in 5 of 9 models, concomitant with downregulation of pERK. The preserved tumor heterogeneity and genomic complexity of PDXs provides an ideal preclinical platform to model strategic combinations of targeted regimens for KRAS-mt lung cancer.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e20561
Interrogating MEK inhibition in a KRAS-mutant lung cancer patient-derived xenograft (PDX) resource.
E20561 Background: Constitutively activating KRAS mutations (mt) comprise ~28% of lung adenocarcinoma. Despite their accepted role as oncogenic drivers, effective targeted intervention remains elusive. KRAS mts are heterogeneous, with multiple amino acid substitutions differentially associated with patient smoking status and tumor biology, modified further by variable gene amplification levels and co-mt patterns. To identify characteristics of KRAS-mt lung cancers that benefit from MEK inhibition, we investigated the activity of trametinib in a heterogeneous series of KRAS-mt PDX models selected for differences in genomic makeup. Methods: Clinically annotated patient tumor (biopsy, resection or pleural effusion) was implanted subcutaneously into the flank of NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. The resultant PDXs were analyzed for driver mts (JAX 358 CTP panel); copy number variants and global RNA expression (Affymetrix arrays; RNA sequencing). PDX cohorts (n = 6-10) were treated with trametinib at 2-3mg/kg p.o. QDx5/week for 4 weeks, with follow-up until tumors reached pre-determined size. Parallel pharmacodynamic (PD) studies were conducted at 4 & 24h in select models by immunoblotting. Results: To date, 18 KRAS-mt PDX lung cancer models have been established, harboring KRAS G12C, G12D, G12A, G12S or G13R substitutions. 16 models co-harbored TP53mts. Other co-mts of interest included STK11, ATM, Keap1 & BRCA1/2 disrupting mutations, and one model with PI3K E542K. 37% exhibited KRAS gene amplification. Trametinib induced statistically significant tumor growth inhibition in 5 of 9 models tested to date. Characteristics of responsive models included non-G12C KRAS mt with concurrent gene amplification. PD analysis revealed reduction in both MEK and ERK phosphorylation in responsive models. Non-responders showed negligible effect on pERK. Conclusions: In KRAS-mt lung cancer PDX models, single-agent trametinib resulted in partial growth inhibition in 5 of 9 models, concomitant with downregulation of pERK. The preserved tumor heterogeneity and genomic complexity of PDXs provides an ideal preclinical platform to model strategic combinations of targeted regimens for KRAS-mt lung cancer.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 5079
Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421.
5079 Background: Prostate specific antigen (PSA) and bone scan changes are often used as components of primary endpoints in phase II trials of mCRPC. However, they do not reliably capture drug activity, as suggested by multiple phase III trials that failed to validate promising activity in phase II trials. Recently, an association between RECIST 1.0 changes and overall survival (OS) in men with mCRPC receiving docetaxel was observed. We externally validated the prognostic impact of RECIST 1.0 changes on OS. Methods: S0421 was a phase III trial in men with mCRPC men treated with docetaxel and prednisone plus either placebo or atrasentan. Individual patient data from both arms of were combined for analysis since no differences in outcomes were observed. Cox proportional hazards regression evaluated the association of RECIST outcomes within 120 days, i.e. unconfirmed partial response (PR), stable disease (SD) and progressive disease (PD) with OS from day 120. The analysis was adjusted for selected major baseline prognostic factors: hemoglobin, alkaline phosphatase, PSA, treatment arm, performance status, visceral disease, progression type, pain and Gleason score. All tests were two-sided and P ≤ 0.05 was considered statistically significant. Results: Of 1038 eligible patients on S0421, 469 had measurable disease. Of these, 377 had RECIST assessments within 120 days after starting therapy. From day 120, 23 patients had PD, 230 had SD, and 73 had ≥ PR (n = 73). Median OS of was 7.1, 13.4 and 16.3 months, respectively (p = 0.004). After adjusting for baseline factors, RECIST changes remained significantly associated with OS (p = 0.002). For every 10% increase in lesion size, the hazard of dying after day 120 increased by 6.3% (95% CI: 2.3% to 10.5%, p = 0.0018), after adjusting for prognostic factors. Conclusions: This analysis provides external validation of the association of RECIST 1.0 changes with OS in men with mCRPC receiving docetaxel-based chemotherapy. Given that current imaging is increasingly detecting measurable disease, a robust and objective signal of activity represented by RECIST changes should be shown in phase II trials before launching phase III trials.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 5079
Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421.
5079 Background: Prostate specific antigen (PSA) and bone scan changes are often used as components of primary endpoints in phase II trials of mCRPC. However, they do not reliably capture drug activity, as suggested by multiple phase III trials that failed to validate promising activity in phase II trials. Recently, an association between RECIST 1.0 changes and overall survival (OS) in men with mCRPC receiving docetaxel was observed. We externally validated the prognostic impact of RECIST 1.0 changes on OS. Methods: S0421 was a phase III trial in men with mCRPC men treated with docetaxel and prednisone plus either placebo or atrasentan. Individual patient data from both arms of were combined for analysis since no differences in outcomes were observed. Cox proportional hazards regression evaluated the association of RECIST outcomes within 120 days, i.e. unconfirmed partial response (PR), stable disease (SD) and progressive disease (PD) with OS from day 120. The analysis was adjusted for selected major baseline prognostic factors: hemoglobin, alkaline phosphatase, PSA, treatment arm, performance status, visceral disease, progression type, pain and Gleason score. All tests were two-sided and P ≤ 0.05 was considered statistically significant. Results: Of 1038 eligible patients on S0421, 469 had measurable disease. Of these, 377 had RECIST assessments within 120 days after starting therapy. From day 120, 23 patients had PD, 230 had SD, and 73 had ≥ PR (n = 73). Median OS of was 7.1, 13.4 and 16.3 months, respectively (p = 0.004). After adjusting for baseline factors, RECIST changes remained significantly associated with OS (p = 0.002). For every 10% increase in lesion size, the hazard of dying after day 120 increased by 6.3% (95% CI: 2.3% to 10.5%, p = 0.0018), after adjusting for prognostic factors. Conclusions: This analysis provides external validation of the association of RECIST 1.0 changes with OS in men with mCRPC receiving docetaxel-based chemotherapy. Given that current imaging is increasingly detecting measurable disease, a robust and objective signal of activity represented by RECIST changes should be shown in phase II trials before launching phase III trials.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 9088
Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers.
9088 Background: Lung-MAP (S1400), coordinated by SWOG on behalf of NCTN, is a first-in-kind master “umbrella” protocol in partnership between government, academia, patient advocacy organizations, and industry, designed to simultaneously and independently test multiple biomarker-driven therapies for patients (pts) with chemo-refractory squamous cell lung cancer (SCCA). Methods: Lung-MAP currently includes 3 biomarker-driven sub-studies and one non-match study for pts not eligible to enroll onto a biomarker-driven sub-study. If genomic screening identifies a molecular match, pts are assigned to: S1400B evaluating taselisib, a PI3K inhibitor, S1400C evaluating palbociclib, a CDK 4/6 inhibitor and, S1400D evaluating AZD4547, an FGFR inhibitor. The recently activated non –match sub-study S1400I tests nivolumab + ipilimumab vs. nivolumab alone (S1400E evaluating rilotumumab an HGF monoclonal antibody + erlotinib closed 11/26/2014 and S1400A evaluating MEDI4736 in non-match ptsclosed 12/18/2015). Results: From June 16, 2014 to January 20, 2016, 418 sites opened, 525 pts registered to the screening component of the trial, and 210 pts registered to a sub-study: 116 to S1400A, 17 to S1400B, 36 to S1400C, 24 to S1400D, 9 to S1400E and 6 to S1400I. Demographics: Median age 67(range 35-92); male 68%; ECOG PS 0-1 80%, PS 2 16%; Caucasian 85%, Black 8%, other 8%; never/former/current smokers 3%/60%/33%. Of 507 pts genomically screened, 450 (89%) were successful . Table 1 displays biomarker prevalence and overlap; 60% of pts had no match and 0.2% had all 3. Conclusions: This novel master protocol designed to challenge current drug development paradigms and expedite drug registration, is demonstrating feasibility of genomic screening and confirms anticipated prevalence of targeted alterations in SCCA. Support: Supported in part by NIH/NCI (CA180888, CA180819, CA180820, CA180821), and by Amgen, AstraZeneca, Bristol-Myers Squibb Company, Genentech and Pfizer through the Foundation for the National Institutes of Health, in partnership with Friends of Cancer Research. Clinical trial information: NCT02154490.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 9088
Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers.
9088 Background: Lung-MAP (S1400), coordinated by SWOG on behalf of NCTN, is a first-in-kind master “umbrella” protocol in partnership between government, academia, patient advocacy organizations, and industry, designed to simultaneously and independently test multiple biomarker-driven therapies for patients (pts) with chemo-refractory squamous cell lung cancer (SCCA). Methods: Lung-MAP currently includes 3 biomarker-driven sub-studies and one non-match study for pts not eligible to enroll onto a biomarker-driven sub-study. If genomic screening identifies a molecular match, pts are assigned to: S1400B evaluating taselisib, a PI3K inhibitor, S1400C evaluating palbociclib, a CDK 4/6 inhibitor and, S1400D evaluating AZD4547, an FGFR inhibitor. The recently activated non –match sub-study S1400I tests nivolumab + ipilimumab vs. nivolumab alone (S1400E evaluating rilotumumab an HGF monoclonal antibody + erlotinib closed 11/26/2014 and S1400A evaluating MEDI4736 in non-match ptsclosed 12/18/2015). Results: From June 16, 2014 to January 20, 2016, 418 sites opened, 525 pts registered to the screening component of the trial, and 210 pts registered to a sub-study: 116 to S1400A, 17 to S1400B, 36 to S1400C, 24 to S1400D, 9 to S1400E and 6 to S1400I. Demographics: Median age 67(range 35-92); male 68%; ECOG PS 0-1 80%, PS 2 16%; Caucasian 85%, Black 8%, other 8%; never/former/current smokers 3%/60%/33%. Of 507 pts genomically screened, 450 (89%) were successful . Table 1 displays biomarker prevalence and overlap; 60% of pts had no match and 0.2% had all 3. Conclusions: This novel master protocol designed to challenge current drug development paradigms and expedite drug registration, is demonstrating feasibility of genomic screening and confirms anticipated prevalence of targeted alterations in SCCA. Support: Supported in part by NIH/NCI (CA180888, CA180819, CA180820, CA180821), and by Amgen, AstraZeneca, Bristol-Myers Squibb Company, Genentech and Pfizer through the Foundation for the National Institutes of Health, in partnership with Friends of Cancer Research. Clinical trial information: NCT02154490.
- 1 February 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (4_suppl) , 616
Phase II study of dovitinib in patients (Pts) progressing on anti-vascular endothelial growth factor (VEGF) therapy.
616 Background: Prior work identified the fibroblast growth factor (FGF) pathway as a mediator of resistance to anti-VEGF therapy. We tested dovitinib, an oral inhibitor of both FGFRs and VEGFRs in pts progressing on anti-VEGF treatment. Methods: Pts with measurable advanced colorectal cancer (CRC) or non-small cell lung cancer (NSCLC) with progression despite treatment with an anti-VEGF agent within 56 days, good performance status (PS) and adequate organ function were eligible. A pre-treatment tumor biopsy was followed by treatment with dovitinib 500 mg on a 5 day on / 2 day off schedule for 28-day cycles. The primary endpoint of response (RECIST 1.1) was evaluated every 2 cycles. Secondary endpoints included toxicity and the disease control rate at 8 weeks. Intratumor mRNA expression was analyzed using a Next Generation Sequencing based expression array and circulating angiogenic factors analyzed by a multiplex bead-based assays and ELISAs. Results: Ten pts (9 CRC, 1 NSCLC) treated previously with bevacizumab (8) or ziv-aflibercept (2) enrolled. The study closed with termination of dovitinib development. No responses were observed in 7 evaluable pts; 3 withdrew consent during cycle 1. The best response was stable disease in 1 patient. Common toxicities included gastrointestinal, metabolic, and biochemical derangements. All pts experienced at least 1 grade 3 or higher treatment-related adverse event, most commonly fatigue, elevated GGT, and lymphopenia. Expression of multiple angiogenic mediators was common in tumors progressing on anti-VEGF therapy including high levels of FGFR1 and VEGFA. Dovitinib modulated circulating VEGF pathway components; however, no hyperphosphatemia was observed and plasma FGF2 increased continuously. Conclusions: We found no evidence for the activity of dovitinib in pts with CRC progressing on anti-VEGF therapy and could not confirm potent FGFR inhibition. Toxicities were significant. In tumors progressing despite anti-VEGF therapy, a multitude of pro-angiogenic mediators are expressed, including members of the FGF pathway. Clinical trial information: NCT01676714.
- 1 February 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (4_suppl) , 616
Phase II study of dovitinib in patients (Pts) progressing on anti-vascular endothelial growth factor (VEGF) therapy.
616 Background: Prior work identified the fibroblast growth factor (FGF) pathway as a mediator of resistance to anti-VEGF therapy. We tested dovitinib, an oral inhibitor of both FGFRs and VEGFRs in pts progressing on anti-VEGF treatment. Methods: Pts with measurable advanced colorectal cancer (CRC) or non-small cell lung cancer (NSCLC) with progression despite treatment with an anti-VEGF agent within 56 days, good performance status (PS) and adequate organ function were eligible. A pre-treatment tumor biopsy was followed by treatment with dovitinib 500 mg on a 5 day on / 2 day off schedule for 28-day cycles. The primary endpoint of response (RECIST 1.1) was evaluated every 2 cycles. Secondary endpoints included toxicity and the disease control rate at 8 weeks. Intratumor mRNA expression was analyzed using a Next Generation Sequencing based expression array and circulating angiogenic factors analyzed by a multiplex bead-based assays and ELISAs. Results: Ten pts (9 CRC, 1 NSCLC) treated previously with bevacizumab (8) or ziv-aflibercept (2) enrolled. The study closed with termination of dovitinib development. No responses were observed in 7 evaluable pts; 3 withdrew consent during cycle 1. The best response was stable disease in 1 patient. Common toxicities included gastrointestinal, metabolic, and biochemical derangements. All pts experienced at least 1 grade 3 or higher treatment-related adverse event, most commonly fatigue, elevated GGT, and lymphopenia. Expression of multiple angiogenic mediators was common in tumors progressing on anti-VEGF therapy including high levels of FGFR1 and VEGFA. Dovitinib modulated circulating VEGF pathway components; however, no hyperphosphatemia was observed and plasma FGF2 increased continuously. Conclusions: We found no evidence for the activity of dovitinib in pts with CRC progressing on anti-VEGF therapy and could not confirm potent FGFR inhibition. Toxicities were significant. In tumors progressing despite anti-VEGF therapy, a multitude of pro-angiogenic mediators are expressed, including members of the FGF pathway. Clinical trial information: NCT01676714.